Contact: Alexander Shtifman
Phone: 617-713-8989

PCMM/IDI Principal Investigator Judy Lieberman, M.D., Ph.D., and postdoctoral fellow Fabio Petrocca, M.D., have each been awarded FY2008 Research Grants as a part of the Department of Defense's Congressionally Directed Medical Research Programs (CDMRP).  As a part of the Breast Cancer Research Program (BCRP), Judy Lieberman was awarded The BCRP Idea Award.  This award supports highly innovative, high-risk/high‐reward research that could ultimately lead to critical discoveries or major advancements that will accelerate the eradication of breast cancer.  Investigators at all academic levels (or equivalent) were eligible to submit proposals.  She was one of sixty‐one (61) recipients among 1,015 applicants for the FY2008 BCRP Idea Award.

The BCRP challenges the scientific community to design innovative research that will foster new directions for, address neglected issues in, and bring new investigators into the field of breast cancer research. The BCRP focuses its funding on innovative projects that have the potential to make a significant impact on breast cancer, particularly those involving multidisciplinary and/or multi-institutional collaborations.  The BCRP encourages risk‐taking research, however, all projects must demonstrate solid judgment and rationale.  Appropriations for the BCRP from FY92 through FY08 total $2.2 billion making the CDMRP the second largest funding agency for breast cancer research in the world.

Fabio Petrocca was one of sixty-five (65) recipients among 309 applicants for the FY2008 BCRP Postdoctoral Award. The BCRP Postdoctoral Award mechanism was first offered in FY93 and was designed to enable recent medical or other doctoral degree graduates to obtain the necessary experience to pursue an independent career in breast cancer research.  Under this award mechanism, the postdoctoral trainee is considered the Principal Investigator (PI).  While the PI was not required to have previous experience in breast cancer research, the mentor (in this case Judy Lieberman) was required to possess the appropriate expertise in breast cancer, have current peer reviewed breast cancer funding, and clearly demonstrate a commitment to guiding the new PI's research and training.